Retrophin, LLC Initiates Global Access For RE-024 In Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Published: May 12, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced that it has made RE-024 available to physicians who are treating critically ill patients with pantothenate kinase-associated neurodegeneration (PKAN) worldwide under local “compassionate use” regulations. RE-024 is a replacement therapy for phosphopantothenate, the reaction product and substrate that is missing in patients with PKAN.

Help employers find you! Check out all the jobs and post your resume.

Back to news